1Mohan C, Datta SK. Lupus: key pathogenic mechanism and contributing factor. Clin Immunol I mmunopathol, 1995. 77: 201-211.
2Chen F, Maldonado MA, Madaio M. et al. The role of host(endogenous) T cells in chronic graft versus host autoimmune disease. J lmmunol. 1998, 171: 5880-5885.
3Bombardier C, Gladman DD, Urowitz MB. et al. Derivation of the SLEDAI. A disease activity index for lupus patients: the committee on prognosis studies in SLE. Arthritis Rheum. 1992. 35: 630-640.
4Ishida H, Muchamuel J, Sakaguchi S, et al. Contineous administration of anti IL-10 antibodies delay onset of autoimmunity in NZB/W F1 mice. J Exp Med, 1994, 179: 305-310.
5Cairns AP, Crockard AD, Bell AL. lnlerleukin-10 receptor expression in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol, 2003, 21: 83-86.
6Dolores R, Lourdes M, Jose Z, et al. Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. J Autoimmun, 1995, 8: 587-600.
7Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukilt-10 monoclonal antibody administration in systemic lupus erythematosus.Arthritis Rheum,2000, 43: 1790-1800.
5Semple JW.Immune pathophysiology of autoimmune thrombocytopenic purpura[J].Blood Rev,2002,16(1):9-12.
6Fukushima T,Dong L,Sakai T,et al.Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus[J].Lupus,2008,17(3):210-214.
7Kiefel V,Santoso S,Kaufmann E,et al.Auto antibodies against platelet glycoprotein Ib/IX:a frequent findings in autoimmune thrombocytopenic purpura[J].Br J Haematol,1991,79(2):256-262.
8Schmitz G,Rothe G,Rnf A.European working group on clinical cell analysis:consensus protocol for the flow cytometric characterization of platelet function[J].Thromb Haemost,1998,79(5):885-896.
